PDCD1 and neoplasm: One example is atezolizumab, a monoclonal antibody which binds to tumor cells expressing PD-L1; this inhibits binding with T-cell expressed PD-1 and B7.1 receptors, allowing activation and proliferation of T-cells and enhanced function and memory cell formation to fight the tumor.